Literature DB >> 27888155

Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population.

Elena Ramírez1, Teresa Bellón2, Hoi Y Tong3, Alberto M Borobia3, Francisco J de Abajo4, Victoria Lerma4, Miguel A Moreno Hidalgo5, José L Castañer5, Rosario Cabañas6, Ana Fiandor6, Jessica González-Ramos7, Pedro Herranz7, Lucía Cachafeiro8, Carlos González-Herrada9, Olga González9, José A Aramburu10, Olga Laosa11, Rafael Hernández3, Antonio J Carcas3, Jesús Frías12.   

Abstract

Aromatic antiepileptic drugs (AEDs) are among the drugs most frequently involved in severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms (DRESS). This study investigated the associations between the genetic polymorphisms of HLA class-I and AED-induced SCARs in the Spanish population. HLA class-I genotypes were determined in AED (phenytoin[PHT],lamotrigine[LTG],carbamazepine[CBZ],phenobarbital[PB])-induced SJS/TEN (n=15) or DRESS (n=12) cases included in the Spanish SCAR registry, PIELenRed. There were 3 control groups: (A)tolerant to a single AED, (B)tolerant to any AED, and (C)Spanish population controls. For SJS/TEN, concomitant HLA-A*02:01/Cw15:02 alleles were significantly associated with PHT-cases compared to control groups B and C [(B)odds ratio(OR):14.75, p=0.009;(C)OR:27.50, p<0.001], and were close to significance with respect to control group A (p=0.060). The genotype frequency of the HLA-B*38:01 was significantly associated with PHT-LTG-cases compared with the 3 groups of controls [(A)OR:12.86, p=0.012;(B)OR:13.81; p=0.002;(C)OR:14.35, p<0.001], and with LTG-cases [(A)OR:147.00, p=0.001;(B)OR:115.00, p<0.001;(C)OR:124.70, p<0.001]. We found the HLA-B*15:02 allele in a Spanish Romani patient with a CBZ-case. The HLA-A*11:01 was significantly associated with CBZ-cases [(A)OR:63.89, p=0.002;(B)OR:36.33, p=0.005;(C)OR:28.29, p=0.007]. For DRESS, the HLA-A*24:02 genotype frequency was statistically significant in the PHT-LTG-cases [(A)OR:22.56, p=0.003;(B)OR:23.50. p=0.001; (C)OR:33.25, p<0.001], and in the LTG-cases [(A),OR:49.00, p=0.015;(B)OR:27.77, p=0.005; (C)OR:34.53, p=0.002]. HLA-A*31:01 was significantly associated with the CBZ-cases [(A)OR:22.00, p=0.047;(B)OR:29.50, p=0.033;(C)OR:35.14, p=0.006]. In conclusion, we identified several significant genetic risk factors for the first time in the Spanish Caucasian population: HLA-A*02:01/Cw*15:02 combination as a risk factor for PHT-induced SJS/TEN, HLA-B*38:01 for LTG- and PHT- induced SJS/TEN, HLA-A*11:01 for CBZ-induced SJS/TEN, and HLA-A*24:02 for LTG- and PHT- induced DRESS. The strong association between HLA*31:01 and CBZ-DRESS in Europeans was confirmed in this study.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aromatic antiepileptic drugs; Carbamazepine (PubChem CID: 2554); Drug reaction with eosinophilia and systemic symptoms; Human leukocyte antigen; Lamotrigine (PubChem CID: 3878); Phenobarbital (PubChem CID: 4763); Phenytoin (PubChem CID: 1775); Severe cutaneous adverse drug reactions; Stevens-Johnson syndrome; Toxic epidermal necrolysis

Mesh:

Substances:

Year:  2016        PMID: 27888155     DOI: 10.1016/j.phrs.2016.11.027

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  15 in total

Review 1.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 2.  Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS.

Authors:  Hannah Stirton; Neil H Shear; Roni P Dodiuk-Gad
Journal:  Biomedicines       Date:  2022-04-26

Review 3.  Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.

Authors:  Teresa Bellón
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.228

Review 4.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 5.  An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity.

Authors:  Chun-Bing Chen; Riichiro Abe; Ren-You Pan; Chuang-Wei Wang; Shuen-Iu Hung; Yi-Giien Tsai; Wen-Hung Chung
Journal:  J Immunol Res       Date:  2018-02-13       Impact factor: 4.818

Review 6.  Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Akito Hasegawa; Riichiro Abe
Journal:  F1000Res       Date:  2020-06-16

7.  Genetic markers of severe cutaneous adverse reactions.

Authors:  Jae-Woo Jung; Jae-Yeol Kim; In-Won Park; Byoung-Whui Choi; Hye-Ryun Kang
Journal:  Korean J Intern Med       Date:  2018-06-22       Impact factor: 2.884

8.  Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report.

Authors:  Wei Zuo; Li-Ping Wen; Jun Li; Dan Mei; Qiang Fu; Bo Zhang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 9.  Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

Authors:  Rebecca Pavlos; Katie D White; Celestine Wanjalla; Simon A Mallal; Elizabeth J Phillips
Journal:  Immunol Allergy Clin North Am       Date:  2017-11       Impact factor: 3.479

10.  Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015.

Authors:  Yanru Du; Jiahe Lin; Jingzan Shen; Siqi Ding; Mengqian Ye; Li Wang; Yi Wang; Xinshi Wang; Niange Xia; Rongyuan Zheng; Hong Chen; Huiqin Xu
Journal:  BMC Pharmacol Toxicol       Date:  2019-01-14       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.